Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 1, 2016, Pages

  Kew, Kayleigh M ^a   Dahri, Karen ^b,c  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; LONG ACTING BETA 2 AGONIST; LONG ACTING MUSCARINIC ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ADULT; ASTHMA; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRY POWDER INHALER; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG FUNCTION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOFT MIST INHALER; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; COMBINATION DRUG THERAPY; DISEASE COURSE; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; MIDDLE AGED; PROCEDURES;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; ASTHMA; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIOTROPIUM BROMIDE;

EID: 84966280695     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011721.pub2     Document Type: Review

References (122)

1. 2-agonists (LABAs) in patients with symptomatic severe asthma: efficacy by level of airway obstruction. Allergo Journal 2014;23(6):57.
2. 2-agonists. CHEST Annual Conference; 2013 October 26-31; Chicago. 2013.
3. Casale TB, Dahl R, Virchow JC, Engel M, Moroni-Zentgraf P, Luehmann R, et al. Tiotropium respimat add-on therapy reduces exacerbation risk in patients with symptomatic moderate to severe asthma, independent of t helper 2 status. American Thoracic Society International Conference; 2015 May 15-20; Denver. 2015:A4193.
4. Corren J, Frew A, Engel M, Schmidt H, Moroni-Zentgraf P, Kerstjens HAM. Tiotropium as add-on therapy to ICS+LABA in patients with symptomatic severe asthma: spirometric assessment over 24 hours [Abstract]. American College of Chest Physicians Annual Meeting; 2013 Oct 26-31; Chicago. 2013; Vol. 144:91A.
5. Corren J, Murphy KR, Bensch G, Dahl R, Paggiaro P, Engel M, et al. Once-daily tiotropium Respimat decreases the risk of exacerbations, independent of baseline characteristics, in patients with symptomatic severe asthma without evidence of chronic obstructive pulmonary disease. Journal of General Internal Medicine 2014;29:S157-8.
6. Dahl R, Casale T, Pizzichini E, Vandewalker M, Virchow JC, Engel M, et al. Once-daily tiotropium Respimat as add-on to at least medium-to high-dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status. Thorax 2014;69(Suppl 2):A177-8.
7. Dahl R, Doherty DE, Corren J, Karpel J, Kerstjens HAM, Engel M, et al. Once-daily tiotropium respimat improves lung function in patients with severe symptomatic asthma independent of leukotriene modifier use. The Journal of Allergy and Clinical Immunology 2014;133(2):AB5.
8. Dahl R, Paggiaro P, Engel M, Sigmund R, Moroni-Zentgraf P, Bateman E, et al. Once-daily tiotropium improves lung function and reduces risk of asthma exacerbation/worsening in patients with symptomatic asthma, regardless of allergic status. Allergy 2013;68(s98):40-1.
9. Doherty DE, Castro M, Moroni-Zentgraf P, Engel M, Luehmann R, Buhl R. Tiotropium respimat add-on therapy improves lung function, as measured by peak expiratory flow, in adult patients across severities of symptomatic asthma. American Thoracic Society International Conference; 2015 May 15-20; Denver. 2015:A4258.
10. Doherty DE, Tashkin DP, Harrison T W, Engel M, Schmidt H, Moroni-Zentgraf P, et al. Improvements in lung function with tiotropium as add-on controller therapy to ICS+LABA for patients with symptomatic severe asthma. Chest 2013;144(4):88A.
11. FitzGerald JM, Engel M, Moroni-Zentgraf P, Luehmann R, Bleecker ER. Once-daily tiotropium respimat add-on therapy improves symptom control across severities of symptomatic asthma, independent of allergic status. American Thoracic Society Internation Conference; 2015 May 15-20; Denver. 2015:A4263.
12. Frith P, Price D, Bateman E, Paggiaro P, Kaplan A, Engel M, et al. Efficacy of once-daily tiotropium respimat 5 μg from five phase III trials in adults with symptomatic asthma. Respirology 2015;20(Suppl S2):137.
13. Halpin DMG, Bateman ED, Moroni-Zentgraf P, Engel M, Schmidt H, Kerstjens HAM. Tiotropium is effective in patients with severe asthma without evidence of chronic obstructive pulmonary disease. Thorax 2013;68(Suppl 3):A152.
14. Halpin DMG, Bateman ED, Tashkin DP, Engel M, Dahl R, Paggiaro P, et al. Tiotropium decreases the risk of exacerbations in patients with symptomatic asthma regardless of baseline characteristics including markers of allergic status. Thorax 2013;68(Suppl 3):A149.
15. Hashimoto S, Engel M, Schmidt H, Moroni-Zentgraf P, Kerstjens HAM. Once-daily tiotropium as add-on to ICS + LABA for patients with severe symptomatic asthma: baseline characteristics in Japanese patients. Respirology 2013;18(S2):88.
16. Hozawa S, Kerstjens HAM, Tashkin DP, Engel M, Ronald D, Pierluigi P, et al. Tiotropium decreases the risk of exacerbations in patients with symptomatic asthma regardless of baseline characteristics. Respirology 2013;18(Suppl 3):A149.
17. Kerstjens H, Dahl R, Beck E, Vandewalker M, Engel M, Sigmund R, et al. Tiotropium reduces asthma exacerbations in patients with uncontrolled asthma and persistent airflow obstruction despite treatment in accordance with guidelines. Respirology 2012;17(Suppl 2):A483.
18. Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium Respimat® add-on therapy to inhaled corticosteroids (ICS) + long-acting B2-agonists (LABAS) in patients with symptomatic severe asthma: efficacy by level of airway obstruction [Abstract]. American Journal of Respiratory and Critical Care Medicine 2014;189:A1312.
19. Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. New England Journal of Medicine 2012;367(13):1198-207.
20. Kerstjens HAM, Engel M, Moroni-Zentgraf P, Schmidt H, Bateman E. Tiotropium added to inhaled corticosteroids and long-acting beta(2)-agonists reduces episodes of asthma worsening, irrespective of selected patient baseline characteristics. Allergy 2013;68(s98):41.
21. Kerstjens HAM, Paggiaro P, Vandewalker M, Beck E, Engel M, Sigmund R, et al. Tiotropium provides sustained bronchodilation in patients with uncontrolled asthma and persistent airflow obstruction despite treatment in accordance with guidelines [Abstract]. Respirology 2012;17(Suppl 2):6 [221].
22. NCT00772538 . A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma. https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001413-14/results (accessed 23 June 2015).
23. NCT00772538 . Evaluation of tiotropium 5 μg/day delivered via the Respimat® inhaler over 48 weeks in patients with severe persistent asthma on top of usual care (study I). https://clinicaltrials.gov/ct2/show/NCT00772538 (accessed 22 June 2015).
24. Price D, Engel M, Moroni-Zentgraf P, Schmidt H, Dahl R, Paggiaro P, et al. Once-daily tiotropium respimat add-on to ICS + LABA improves symptom control and reduces exacerbations in patients with symptomatic asthma. Thorax 2014;69(Suppl 2):A49-50.
25. Tashkin D, Moroni-Zentgraf P, Engel M, Schmidt H, Kerstjens H. Once-daily tiotropium respimat add-on to ICS+LABA reduces risk of severe exacerbation and asthma worsening in patients with asthma, independent of degree of airflow obstruction. Chest 2014;146(4):18A.
26. 2-agonists. Chest 2013;144(4):90A.
27. Vandewalker ML, Engel M, Schmidt H, Siebold W, Moroni-Zentgraf P, Kerstjens H, et al. Efficacy of tiotropium in patients with asthma in relation to allergic status [Abstract]. The Journal of Allergy and Clinical Immunology 2013;131(2):AB1.
28. Vandewalker ML, Karpel J, Bensch G, Ford L, Engel M, Sigmund R, et al. Once-daily tiotropium Respimat add-on to maintenance therapy improves lung function in patients with moderate or severe symptomatic asthma, independent of T helper 2 inflammatory status. Annals of Allergy, Asthma & Immunology 2014;113(5):A105-6.
29. 2008-001414-25 . A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma. https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001414-25/results (accessed 23 June 2015).
30. 2-agonists (LABAs) in patients with symptomatic severe asthma: efficacy by level of airway obstruction. Allergo Journal 2014;23(6):57.
31. 2-agonists. CHEST Annual Conference; 2013 October 26-31. 2013.
32. Casale TB, Dahl R, Virchow JC, Engel M, Moroni-Zentgraf P, Luehmann R, et al. Tiotropium respimat add-on therapy reduces exacerbation risk in patients with symptomatic moderate to severe asthma, independent of t helper 2 status. American Thoracic Society International Conference; 2015 May 15-20; Denver. 2015:A4193.
33. Corren J, Frew A, Engel M, Schmidt H, Moroni-Zentgraf P, Kerstjens HAM. Tiotropium as add-on therapy to ICS+LABA in patients with symptomatic severe asthma: spirometric assessment over 24 hours [Abstract]. American College of Chest Physicians Annual Meeting; 2013 Oct 26-31; Chicago, Illinois. 2013; Vol. 144:91A.
34. Corren J, Murphy KR, Bensch G, Dahl R, Paggiaro P, Engel M, et al. Once-daily tiotropium respimat decreases the risk of exacerbations, independent of baseline characteristics, in patients with symptomatic severe asthma without evidence of chronic obstructive pulmonary disease. Journal of General Internal Medicine 2014;29:S157-8.
35. Dahl R, Casale T, Pizzichini E, Vandewalker M, Virchow JC, Engel M, et al. Once-daily tiotropium Respimat as add-on to at least medium-to high-dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status. Thorax 2014;69(Suppl 2):A177-8.
36. Dahl R, Doherty DE, Corren J, Karpel J, Kerstjens HAM, Engel M, et al. Once-daily tiotropium respimat improves lung function in patients with severe symptomatic asthma independent of leukotriene modifier use. The Journal of Allergy and Clinical Immunology 2014;133(2):AB5.
37. Dahl R, Paggiaro P, Engel M, Sigmund R, Moroni-Zentgraf P, Bateman E, et al. Once-daily tiotropium improves lung function and reduces risk of asthma exacerbation/worsening in patients with symptomatic asthma, regardless of allergic status. Allergy 2013;68(s98):40-1.
38. Doherty DE, Castro M, Moroni-Zentgraf P, Engel M, Luehmann R, Buhl R. Tiotropium respimat add-on therapy improves lung function, as measured by peak expiratory flow, in adult patients across severities of symptomatic asthma. American Thoracic Society International Conference; 2015 May 15-20; Denver. 2015:A4258.
39. Doherty DE, Tashkin DP, Harrison T W, Engel M, Schmidt H, Moroni-Zentgraf P, et al. Improvements in lung function with tiotropium as add-on controller therapy to ICS+LABA for patients with symptomatic severe asthma. Chest 2013;144(4):88A.
40. FitzGerald JM, Engel M, Moroni-Zentgraf P, Luehmann R, Bleecker ER. Once-daily tiotropium respimat add-on therapy improves symptom control across severities of symptomatic asthma, independent of allergic status. American Thoracic Society Internation Conference; 2015 May 15-20; Denver. 2015:A4263.
41. Frith P, Price D, Bateman E, Paggiaro P, Kaplan A, Engel M, et al. Efficacy of once-daily tiotropium Respimat 5 μg from five phase III trials in adults with symptomatic asthma. Respirology 2015;20(Suppl S2):137.
42. Halpin DMG, Bateman ED, Moroni-Zentgraf P, Engel M, Schmidt H, Kerstjens HAM. Tiotropium is effective in patients with severe asthma without evidence of chronic obstructive pulmonary disease. Thorax 2013;68(Suppl 3):A152.
43. Halpin DMG, Bateman ED, Tashkin DP, Engel M, Dahl R, Paggiaro P, et al. Tiotropium decreases the risk of exacerbations in patients with symptomatic asthma regardless of baseline characteristics including markers of allergic status. Thorax 2013;68(Suppl 3):A149.
44. Hashimoto S, Engel M, Schmidt H, Moroni-Zentgraf P, Kerstjens HAM. Once-daily tiotropium as add-on to ICS + LABA for patients with severe symptomatic asthma: Baseline characteristics in Japanese patients. Respirology 2013;18(S2):88.
45. Hozawa S, Kerstjens HAM, Tashkin DP, Engel M, Ronald D, Pierluigi P, et al. Tiotropium decreases the risk of exacerbations in patients with symptomatic asthma regardless of baseline characteristics. Respirology 2013;18(Suppl 3):175.
46. Kerstjens H, Dahl R, Beck E, Vandewalker M, Engel M, Sigmund R, et al. Tiotropium reduces asthma exacerbations in patients with uncontrolled asthma and persistent airflow obstruction despite treatment in accordance with guidelines. Respirology 2012;17(Suppl 2):16.
47. Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium Respimat® add-on therapy to inhaled corticosteroids (ICS) + long-acting B2-agonists (LABAS) in patients with symptomatic severe asthma: efficacy by level of airway obstruction [Abstract]. American Journal of Respiratory and Critical Care Medicine 2014;189:A1312.
48. Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. New England Journal of Medicine 2012;367(13):1198-207.
49. 2-agonists (LABAS) in patients with symptomatic severe asthma: Efficacy by level of airway obstruction. American Thoracic Society International Conference; 2014 May 16-21; San Diego. 2014:A1312.
50. Kerstjens HAM, Engel M, Moroni-Zentgraf P, Schmidt H, Bateman E. Tiotropium added to inhaled corticosteroids and long-acting beta(2)-agonists reduces episodes of asthma worsening, irrespective of selected patient baseline characteristics. Allergy 2013;68(s98):41.
51. Kerstjens HAM, Paggiaro P, Vandewalker M, Beck E, Engel M, Sigmund R, et al. Tiotropium provides sustained bronchodilation in patients with uncontrolled asthma and persistent airflow obstruction despite treatment in accordance with guidelines [Abstract]. Respirology 2012;17(Suppl 2):6 [221].
52. NCT00776984 . Evaluation of tiotropium 5 μg/day delivered via the Respimat® inhaler over 48 weeks in patients with severe persistent asthma on top of usual care (study II). https://clinicaltrials.gov/ct2/show/NCT00776984 (accessed 22 June 2015).
53. Price D, Engel M, Moroni-Zentgraf P, Schmidt H, Dahl R, Paggiaro P, et al. Once-daily tiotropium Respimat add-on to ICS + LABA improves symptom control and reduces exacerbations in patients with symptomatic asthma. Thorax 2014;69(Suppl 2):A49-50.
54. Tashkin D, Moroni-Zentgraf P, Engel M, Schmidt H, Kerstjens H. Once-daily tiotropium Respimat add-on to ICS+LABA reduces risk of severe exacerbation and asthma worsening in patients with asthma, independent of degree of airflow obstruction. Chest 2014;146(4):18A.
55. 2-agonists. Chest 2013;144(4):90A.
56. Vandewalker ML, Engel M, Schmidt H, Siebold W, Moroni-Zentgraf P, Kerstjens H, et al. Efficacy of tiotropium in patients with asthma in relation to allergic status [Abstract]. The Journal of Allergy and Clinical Immunology 2013;131(2):AB1.
57. Vandewalker ML, Karpel J, Bensch G, Ford L, Engel M, Sigmund R, et al. Once-daily tiotropium Respimat add-on to maintenance therapy improves lung function in patients with moderate or severe symptomatic asthma, independent of T helper 2 inflammatory status. Annals of Allergy, Asthma and Immunology 2014;113(5):A105-6.
58. NCT02127697 . Study of efficacy and safety of NVA237 in patients with poorly controlled asthma. https://clinicaltrials.gov/ct2/show/NCT02127697 (accessed 22 June 2015).
59. Ichinose M, Ohta K, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, et al. Once-daily tiotropium respimat is well tolerated and efficacious over 52 weeks in Japanese patients with symptomatic asthma receiving inhaled corticosteroids (ICS) + long-acting B2-agonist (LABA): A randomized, double-blind, placebo-controlled study. Respirology 2014;19(Suppl 3):65.
60. NCT01340209 . Evaluation of tiotropium 2.5 and 5 μg once daily delivered via the Respimat inhaler compared to placebo in patients with moderate to severe persistent asthma. https://clinicaltrials.gov/ct2/show/NCT01340209 (accessed 22 June 2015).
61. Ohta K, Ichinose M, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, et al. Long-term once-daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: A randomised, placebo-controlled study. PLOS ONE 2015;10(4):e0124109.
62. Ohta K, Ichinose M, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, et al. Once-daily tiotropium respimat® is well tolerated and efficacious over 52 weeks in Japanese patients with symptomatic asthma receiving inhaled corticosteroids (ICS ± long-acting B2-agonist (LABA): a randomized, double-blind, placebo-controlled study [Abstract]. American Journal of Respiratory and Critical Care Medicine 2014;189:A1311.
63. 2009-018006-21 . A phase II, randomised, double- blind, placebo controlled, cross-over efficacy and safety comparison of tiotropium 5 μg administered once daily (in the evening) and tiotropium 2.5 μg administered twice daily delivered by the Respimat® inhaler for four weeks versus placebo in patients with moderate persistent asthma. https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-018006-21/results (accessed 23 June 2015).
64. 2010-018471-26 . A phase II randomised, double-blind, placebo controlled, cross-over efficacy and safety comparison of three doses of tiotropium inhalation solution delivered via Respimat® inhaler (1.25, 2.5 and 5.0 μg once daily) versus placebo in patients with moderate persistent asthma. https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018471-26/results (accessed 23 June 2015).
65. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. The Journal of Allergy and Clinical Immunology 2011;128(2):315-22.
66. Beeh KM, Ablinger O, Moroni-Zentgraf P, Hollaenderova Z, Pivovarova A, Engel M, et al. Once-daily add-on tiotropium: a dose-finding trial in adult patients with moderate persistent asthma. Allergy 2013;68(s97):376-7.
67. Beeh KM, Moroni-Zentgraf P, Ablinger O, Hollaenderova Z, Unseld A, Engel M, et al. Tiotropium Respimat in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respiratory Research 2014;15:61.
68. Dusser D, Buhl R, Castro M, Kerstjens H, Paggiaro P, Engel M, et al. Once-daily tiotropium respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis. European Respiratory Journal 2014;44(Suppl 58):P905.
69. Fardon T, Haggart K, Lee D K C, Lipworth B J. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respiratory Medicine 2007;101(6):1218-28.
70. FitzGerald J M, Kerstjens H, Paggiaro P, Ohta K, Ichinose M, Moroni-Zentgraf P, et al. Once-daily tiotropium respimat add-on to ICS+/-LABA improves control across asthma severities. European Respiratory Journal 2014;44(Suppl 58):1894.
71. Haggart K, Fardon TC, Lee DKC, Lipworth BJ. Stepping down inhaled steroids in severe asthma with long acting bronchodilators: utilising effort dependent and independent measures of pulmonary function [Abstract]. British Thoracic Society Winter Meeting; 2004 Dec 1-3; London, United Kingdom. 2004; Vol. 59:ii72.
72. Haughney J, Vandewalker M, Meltzer E, Paggiaro P, Engel M, Unseld A, et al. Once-daily tiotropium Respimat: safety and tolerability results from five phase iii trials in adults with symptomatic asthma. Thorax 2014;69(Suppl 2):A178-9.
73. Jiang XP, Tan HY. Clinical observation for triple therapy in the treatment of 30 patients with bronchial asthma. Hunan Zhongyi Zazhi [Hunan Journal of Traditional Chinese Medicine] 2006;22:17-8.
74. Kerstjens HA, Disse B, Schröder-Babo W, Bantje T A, Gahlemann M, Sigmund R, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. The Journal of Allergy and Clinical Immunology 2011;128(2):308-14.
75. Casale T, Bleecker E, Meltzer E, Pizzichini E, Schmidt O, Bateman E, et al. Phase III trials to investigate tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Trial design and planned statistical analyses. Allergy 2013;68(s97):377.
76. Casale T, Carr WW, Greos L, Engel M, Bour LJ, Moroni-Zentgraf P, et al. 24-hour lung function response to tiotropium Respimatadd-on to maintenance therapy in symptomatic patients with moderate persistent asthma. Annals of Allergy, Asthma & Immunology 2014;113(5):A108.
77. Casale TB, Bateman ED, Dahl R, Pizzichini E, Vandewalker ML, Virchow JC, et al. Tiotropium respimat add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of Th2 inflammatory status. The Journal of Allergy and Clinical Immunology 2014;133(2):AB5.
78. Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. The Lancet Respiratory Medicine 2015;3(5):367-76.
79. Kerstjens HAM, Bleecker E, Meltzer E, Casale T, Pizzichini E, Schmidt O, et al. Tiotropium as add-on to inhaled corticosteroids significantly improves asthma control as reflected by the ACQ responder rate. European Respiratory Society Annual Congress; 2013 7-11 Sept; Barcelona. 2013.
80. Lee LA, Yang S, Kerwin E, Trivedi R, Edwards LD, Pascoe S. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Respiratory Medicine 2015;109(1):54-62.
81. Lommatzsch M, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Timmer W. Tiotropium Respimat in asthma: evaluation of dosing regimens. Allergo Journal 2014;23(6):57.
82. 2-agonists improves lung function and asthma control and reduces risk of asthma worsening in patients with moderate or severe asthma. Annals of Allergy, Asthma & Immunology 2014;113(5):A107.
83. NCT01573624 . A multi-center, randomized, double-blind, dose-ranging study to evaluate GSK573719 in combination with fluticasone furoate, fluticasone furoate alone, and an active control of fluticasone furoate/vilanterol combination in subjects with asthma. http://clinicaltrials.gov/show/NCT01573624 (accessed 22 June 2015).
84. NCT02039011 . Proof of concept study to evaluate single and chronic dosing effects of ultra-long acting bronchodilator therapy on mannitol challenge in asthmatic patients taking inhaled corticosteroids - MAN02 Ultra-long Acting Bronchodilator Therapy in Asthmatics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-001953-28-GB (accessed 23 June 2015).
85. Paggiaro P, Engel M, Tudoric N, Forstner B, Radeczky E, Zubek V, et al. Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: design and planned analyses [Abstract]. European Respiratory Journal 2013;42(Suppl 57):877s [P4133].
86. Lane M. Tiotropium bromide in asthma patients: an alternative to inhaled long-acting beta-agonists?. Journal of the Royal College of Physicians of Edinburgh 2010;40(4):321-2.
87. Peters S P, Kunselman S J, Icitovic N, Moore W C, Pascual R, Ameredes B T, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. New England Journal of Medicine 2010;363(18):1715-26.
88. Peters SP, Bleecker ER, Kunselman SJ, Icitovic N, Moore WC, Pascual R, et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology 2013;132(5):1068-74.e1.
89. Price D, Bateman ED, Paggiaro P, Kaplan A, Engel M, Schmidt H, et al. Efficacy of once-daily tiotropium Respimat 5 mug from five phase III trials in adults with symptomatic asthma. Thorax 2014;69(Suppl 2):A50.
90. Rajanandh MG, Nageswari A D, Ilango K. Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics 2014;36(4):526-33.
91. Rajanandh MG, Nageswari AD, Ilango K. Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment? A randomized trial. Clinical Therapeutics 2015;37(2):418-26.
92. Rajanandh MG, Nageswari AD, Ilango K. Assessment of various second-line medications in addition to inhaled corticosteroid in asthma patients: a randomized controlled trial. Clinical and Experimental Pharmacology & Physiology 2014;41(7):509-13.
93. Rodrigo GJ, Castro-Rodriguez JA. What is the role of tiotropium in asthma?: a systematic review with meta-analysis [Review]. Chest 2015;147(2):388-96.
94. Salvi S, Bhosle K, Brashier B, Limaye S, Mandrekar S, Gaikwad S, et al. Eight weeks of treatment with tiotropium plus fluticasone (t + f ) produces an equally effective therapeutic response as salmeterol plus fluticasone (s + f) in subjects with moderate-to-severe asthma [Abstract]. European Respiratory Journal 2009;34(Suppl 53):E276.
95. Timmer W, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Buhl R. Once-daily tiotropium Respimat 5 mug is an efficacious 24-h bronchodilator in adults with symptomatic asthma. Respiratory Medicine 2015;109(3):329-38.
96. Vandewalker M, Harper III T, Moroni-Zentgraf P, Engel M, Luhmann R, Bernstein JA. Once-daily tiotropium Respimat add-on therapy improves lung function in adolescent patients with moderate symptomatic asthma, independent of t helper 2 inflammatory status. Annals of Allergy, Asthma & Immunology 2015;115(5 Suppl 1):A54-5.
97. Vogelberg C, Engel M, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Downie J, et al. Once-daily tiotropium Respimat add-on to medium-dose ics is an efficacious 24-hour bronchodilator in adolescent patients with symptomatic asthma. Chest 2014;146(4):698A.
98. Vogelberg C, Leonaviciute-Klimantaviciene M, Vevere V, Vandewalker M, Engel M, Sigmund R, et al. Dose-ranging study of tiotropium as treatment for moderate persistent asthma in adolescents. Allergo Journal 2013;22:389.
99. Yoshida M, Nakano T, Fukuyama S, Matsumoto T, Eguchi M, Moriwaki A, et al. Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes. Pulmonary Pharmacology and Therapeutics 2013;26(2):159-66.
100. NCT01696214 . A pilot study to determine the feasibility and utility of implementing of the full scale TOM trial (SAPS). https://clinicaltrials.gov/ct2/show/NCT01696214 (accessed 22 June 2015).
101. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Beclomethasone versus placebo for chronic asthma. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD002738.pub2]
102. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4]
103. Anderson DE, Kew KM, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD011397.pub2]
104. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma, October 2014. https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/asthma-guideline/ (accessed 16 March 2015).
105. 2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2]
106. 2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2]
107. Electronic Medicines Compendium. License extension 19th September 2014: Spiriva Respimat 2.5 micrograms solution for inhalation. https://www.medicines.org.uk/emc/history/20134 (accessed 16 March 2015).
108. Global Initiative for Asthma. Global strategy for asthma management and prevention. http://www.ginasthma.org/ (accessed 16 March 2015).
109. International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2011. http://theunion.org/what-we-do/publications/technical/global-asthma-report (accessed 16 March 2015).
110. Brozek J, Oxman A, Schünemann H. GRADEpro. Version 3.2 for Windows. Hamilton, Ontario: McMaster University, 2008.
111. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
112. Kerstjens HAM, Engel M, Bateman ED. Tiotropium in asthma [correspondence]. New England Journal of Medicine 2012;367:2552-3.
113. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Archives of Internal Medicine 1999;159(9):941-55.
114. Lipworth BJ. Emerging role of long acting muscarinic antagonists for asthma. British Journal of Clinical Pharmacology 2014;77(1):55-62.
115. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]
116. Moulton BC, Fryer AD. Muscarinic receptor antagonists, from folklore to pharmacology: finding drugs that actually work in asthma and COPD. British Journal of Clinical Pharmacology 2011;163(1):44-52.
117. Royal College of Physicians. Why asthma still kills: the national review of asthma deaths. www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf (accessed 27 March 2015).
118. Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. The Open Respiratory Medicine Journal 2014;8(Suppl 1):59-65.
119. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
120. McIvor RA. Respiratory disorders: chronic obstructive pulmonary disease. In: Gray J editor(s). Therapeutic Choices. 7th Edition. Ottawa: Canadian Pharmaceutical Association, 2014.
121. Tian J, Chen J, Chen R, Chen X. Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis. Respiratory Care 2014;59(5):654-66.
122. 2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD011721]